Home 3 Big Cap Biotechs That Could Trounce Gilead Sciences This Year
 

Keywords :   


3 Big Cap Biotechs That Could Trounce Gilead Sciences This Year

2015-03-01 17:35:43| Biotech - Topix.net

Revlimid was already on pace to deliver sales of more than $5 billion this year as the leading second-line treatment for the indication; the FDA and EU's approval for its use in newly diagnosed patients could mean that sales finish 2015 closer to an annualized $6 billion pace than a $5 billion pace. Celgene should also be able to notch solid sales growth from its third-line multiple myeloma drug Pomalyst and its cancer drug Abraxane.

Tags: this year big sciences

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
27.11topps now psa10
27.11 THE ORAL CIGARETTES SUCK MY WORLD
27.11 E
27.113DS .SD()
27.11181
27.11YAMAHA KUSHITANI LL
27.11tsnomi.com
27.11
More »